DSX Therapeutics and R&D Antibodies Announce Issuance of EU Patents for First-in-Class MABST

share Share

aSeptiMab® is a Candidate Therapeutic That Targets and Neutralizes Microvesicle-Associated iNOS and Halts the Sepsis Cascade

DSX Therapeutics and its close affiliate Research & Diagnostic Antibodies (R&D Ab®) today announce the European Patent Office has published a Decision to grant patent EP1773390B1 “Improved Therapeutic Agent for iNOS Generating Illness,” which is based upon the ability of the Company’s in vivo neutralizing anti-iNOS monoclonal antibody named aSeptiMab® to stop the sepsis pathology. Circulating microvesicle-associated inducible nitric oxide synthase (MV-A iNOS) has been shown to play a central role in the onset of sepsis, and blocking MV-A iNOS with aSeptiMab® has been demonstrated to halt the sepsis cascade prior to organ damage and dysfunction.

At an average cost of $22,500 – 50,000 (25,000-55,000 €) per patient, sepsis is an enormous healthcare burden in the USA, Europe and around the world. According to Dr. Robert Webber, President and CEO, “aSeptiMab® is a first-in-class monoclonal antibody candidate therapeutic that represents a paradigm shift for the treatment of the 25 million people each year worldwide who develop sepsis. Once approved, aSeptiMab® will provide doctors with the first targeted drug that is truly effective at treating this life-threatening hyper-inflammatory condition.”

Together with the patented PliNOSa® IVD test, which measures plasma levels of MV-A iNOS, aSeptiMab® will form the perfect companion diagnostic and targeted therapeutic for dramatically improved personalized medicine in patients at risk for developing sepsis or suffering the onset of the sepsis pathology. Since the PliNOSa® companion IVD test already exists and measures the same molecule in blood that is targeted and neutralized by aSeptiMab®, this first-in-class candidate therapeutic has a significant advantage over other past tested-and-failed sepsis therapies. DSX Therapeutics anticipates starting an expanded Phase I clinical trial on aSeptiMab® in the EU and the USA by late 2016 with the intention of gaining approval by the Conditional Market Approval process from the EMA and the Accelerated Approval Process from the US FDA by 2021.

Source credit: DSX Therapeutics LLC

Published on : Wed, 24 Jun 2015



Related Articles
Radiometer to Sponsor World Sepsis Day 2016

Radiometer is proud to announce that it is sponsoring this year’s World Sepsis Day on the 13th September, continuing its commitment... Read more

Optimizing Sepsis Management in the Intensive Care Unit: An Interview With Jordi Trafi

“Studies continue to show that guiding antibiotic therapy based on the dynamics of PCT levels in the blood will reduce not... Read more

Thermo Fisher Scientific / B·R·A·H·M·S

The U.S. Food and Drug Administration today cleared the expanded use of the Vidas Brahms PCT Assay to help health care providers... Read more

sepsis,paradigm shift, antibody, pathology aSeptiMab® is a first-in-class monoclonal antibody candidate therapeutic that represents a paradigm shift for the treatment of the 25 million people each year worldwide who develop sepsis

No comment


Please login to leave a comment...

Highlighted Products